Lorlatinib monotherapy- Lorlatinib monotherapy for anaplastic lymphoma kinase-positive advanced non- small cell lung cancer previously untreated with a...

https://updates.chemo.org.uk/CDF_Forms/LOR2.html

🚨 Date moving into routine commissioning upd...

Fruquintinib- Fruquintinib for patients with either metastatic or locally advanced and inoperable colorectal cancer who have received 2 or mo...

https://updates.chemo.org.uk/CDF_Forms/FRU1.html

🚨 Moved into routine commissioning - section...

Nivolumab with ipilimumab- Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair def...

https://updates.chemo.org.uk/CDF_Forms/NIV24.html

🚨 Treatment criteria (#2, 9 and 11) updated

Nivolumab in combination with platinum and...- For previously untreated unresectable advanced or recurrent or metastatic squamous cell carcinoma of the oesophagus with a tumo...

https://updates.chemo.org.uk/CDF_Forms/NIV21.html

🚨 Treatment criteria (#9 and 13) updated

Enzalutamide in combination with androgen ...- For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer

https://updates.chemo.org.uk/CDF_Forms/ENZ3.html

🚨 Treatment criteria (#7 and 9) updated

Elranatamab- For the treatment of relapsed or refractory myeloma in adult patients who have relapsed or are refractory to their last anti-my...

https://updates.chemo.org.uk/CDF_Forms/ELR1.html

🚨 Treatment criteria (#9 and 15) updated

Apalutamide in combination with androgen d...- For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are ineligible for chemothe...

https://updates.chemo.org.uk/CDF_Forms/APA2.html

🚨 Treatment criteria (#8 and 10) updated

Abiraterone In combination with androgen d...- For the treatment of newly diagnosed high risk metastatic hormone-sensitive prostate cancer

https://updates.chemo.org.uk/CDF_Forms/ABI4.html

🚨 Treatment criteria (#6 and 10) updated

Darolutamide in combination with androgen ...- For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatmen...

https://updates.chemo.org.uk/CDF_Forms/DARO3.html

🚨 Recommended for routine commissioning, rec...

Isatuximab in combination with bortezomib,...- in combination (with bortezomib, lenalidomide, and dexamethasone) for the treatment of UNTREATED multiple myeloma when a stem c...

https://updates.chemo.org.uk/CDF_Forms/ISA2.html

🚨 Date moving into routine commissioning upd...

Durvalumab- Durvalumab monotherapy for patients with limited- stage small cell lung cancer whose disease has not progressed following plati...

https://updates.chemo.org.uk/CDF_Forms/DUR7.html

🚨 Treatment criterion (#7) and date moving i...

Brigatinib monotherapy- For anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously untreated with an ALK inhibitor

https://updates.chemo.org.uk/CDF_Forms/BRI2.html

🚨 Drug column updated; Treatment criterion (...

Alectinib monotherapy- For anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously untreated with an ALK inhibitor where th...

https://updates.chemo.org.uk/CDF_Forms/ALE1.html

🚨 Drug column updated; Treatment criterion (...

NA- NA

https://updates.chemo.org.uk/CDF_Forms/NHSE Urgent Interim.html

🚨 Removed from CDF weblist